CorMedix (CRMD) stock price, revenue, and financials

CorMedix market cap is $160.2 m, and annual revenue was $283.27 k in FY 2019

$160.2 M

CRMD Mkt cap, 09-Jul-2020

$74.1 K

CorMedix Revenue Q1, 2020
CorMedix Gross profit (Q1, 2020)25.5 K
CorMedix Gross profit margin (Q1, 2020), %34.5%
CorMedix Net income (Q1, 2020)-5.6 M
CorMedix EBIT (Q1, 2020)-5.6 M
CorMedix Cash, 31-Mar-202012.2 M
CorMedix EV148 M

CorMedix Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

12.2k39.7k52.4k31.3k120.0k35.9k41.4k16.5k44.5k39.6k136.2k61.1k23.2k7.6k372.5k163.7k35.3k59.5k74.1k

Cost of goods sold

81.0k54.5k36.7k17.3k101.8k35.4k50.2k187.2k43.9k93.6k18.1k66.7k28.6k33.7k312.4k227.0k21.1k79.0k48.5k

Gross profit

(68.8k)(14.7k)15.8k13.9k18.2k551.0(8.8k)(170.7k)529.0(54.0k)118.1k(5.6k)(5.4k)(26.1k)60.1k(63.3k)14.1k(19.5k)25.5k

Gross profit Margin, %

(564%)(37%)30%45%15%2%(21%)(1034%)1%(137%)87%(9%)(23%)(346%)16%(39%)40%(33%)34%

R&D expense

1.6m1.7m374.9k248.2k255.7k265.0k390.2k760.8k

General and administrative expense

898.0k877.0k536.3k376.6k746.7k551.7k908.7k504.5k

Operating expense total

2.5m2.6m911.1k624.8k1.0m816.8k1.3m1.3m2.9m1.9m1.9m5.5m4.2m4.7m4.3m4.7m9.2m7.6m7.1m8.0m10.2m8.5m10.3m4.9m5.6m5.2m5.6m

EBIT

(2.5m)(2.6m)(911.1k)(627.8k)(1.0m)(816.8k)(1.3m)(1.3m)(2.9m)(1.9m)(1.9m)(5.5m)(4.1m)(4.7m)(4.3m)(4.9m)(9.2m)(7.6m)(7.0m)(8.0m)(10.2m)(8.6m)(10.2m)(4.9m)(5.5m)(5.2m)(5.6m)

EBIT margin, %

(24048%)(4757%)(3554%)(17582%)(3446%)(13110%)(10286%)(29751%)(20602%)(19260%)(5157%)(13118%)(43898%)(113523%)(2749%)(3008%)(15702%)(8687%)(7578%)

Interest expense

26.1k661.2k

Interest income

3.3k2.2k949.0592.0274.0128.0105.061.0521.0987.0645.0543.08.8k25.0k31.6k29.4k32.9k23.4k28.6k37.2k14.8k10.2k5.4k58.8k96.0k92.1k63.7k

Pre tax profit

(2.5m)(2.6m)(910.2k)(624.2k)(1.0m)(1.3m)(2.0m)(2.5m)(16.7m)(5.8m)(5.3m)

Income tax expense

(5.1m)

Net Income

(2.5m)(2.6m)(910.2k)(624.2k)(1.0m)(1.3m)(2.0m)(2.5m)(16.7m)3.5m(5.0m)(5.5m)(4.1m)(4.7m)(4.2m)(4.9m)(9.1m)(7.6m)(5.1m)(10.0m)(10.2m)(8.6m)(10.2m)(5.2m)(696.2k)(5.3m)(5.6m)

CorMedix Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

2.0m835.5k2.4m4.3m11.8m8.1m10.4m17.6m16.4m

Accounts Receivable

493.9k2.3k80.2k315.8k64.1k10.9k35.0

Prepaid Expenses

31.9k30.7k233.0k155.2k379.0k367.2k422.2k446.4k

Inventories

80.0k463.0k376.6k166.7k594.2k428.5k338.5k

Current Assets

2.5m1.1m2.9m5.0m37.1m21.8m13.3m18.7m29.3m

PP&E

11.7k4.7k36.1k41.5k37.9k69.7k186.3k160.9k126.8k

Total Assets

2.6m1.2m3.0m5.1m37.1m21.9m13.5m18.8m29.5m

Accounts Payable

1.0m1.0m939.8k893.4k1.7m1.6m1.8m2.6m1.0m

Dividends Payable

21.1k

Short-term debt

Current Liabilities

1.3m1.6m1.7m1.4m3.1m4.1m6.3m7.8m5.8m

Long-term debt

2.7k

Total Debt

2.7k

Total Liabilities

1.3m1.6m7.0m1.5m3.1m4.1m6.3m13.9m5.8m

Common Stock

11.4k11.4k16.6k22.5k36.0k71.4k108.9k25.7k

Preferred Stock

857.0950.0450.0420.0420.0242.0

Additional Paid-in Capital

44.2m45.9m51.7m79.7m128.3m136.9m159.2m183.7m218.9m

Retained Earnings

(94.4m)(119.2m)(152.2m)(179.0m)(195.4m)

Total Equity

1.2m(475.4k)(4.0m)3.6m34.0m17.8m7.2m4.9m23.6m

Financial Leverage

2.1 x-2.4 x-0.7 x1.4 x1.1 x1.2 x1.9 x3.8 x1.2 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

4.7m2.9m1.9m893.9k992.3k692.7k158.4k483.1k9.2m7.7m5.9m8.8m24.1m14.2m13.2m12.0m9.8m6.8m7.9m5.2m8.2m4.7m6.4m18.3m14.6m20.1m12.2m

Accounts Receivable

14.2k55.0k46.5k69.4k112.9k124.7k344.7k6.1k22.0k75.9k153.5k89.4k8.7k3.5k302.4k34.4k4.0k7.3k

Prepaid Expenses

149.9k99.1k147.5k105.2k72.3k50.0k15.0k29.8k224.0k203.1k140.9k224.3k298.5k327.3k319.2k169.5k470.4k223.3k352.3k392.6k401.9k168.2k595.9k313.0k203.2k526.7k3.6m

Inventories

270.5k63.7k278.0k677.4k461.4k715.0k699.1k333.9k157.5k118.2k94.9k313.1k299.5k578.9k672.9k341.2k419.6k402.7k381.1k294.9k

Current Assets

4.9m3.0m2.0m999.8k1.2m950.2k378.2k1.0m9.7m8.2m6.8m9.7m38.7m39.3m33.6m31.2m28.8m14.9m21.1m13.9m9.4m5.7m7.9m27.1m27.4m33.6m27.3m

PP&E

17.8k14.6k9.9k8.2k6.4k4.1k3.6k3.0k33.6k54.2k46.9k47.0k44.7k41.1k34.8k31.9k75.8k63.2k57.0k71.0k205.3k185.8k178.5k165.9k146.6k134.5k118.6k

Total Assets

4.9m3.0m2.0m1.0m1.3m967.6k395.1k1.0m9.8m8.3m6.8m9.8m38.8m39.3m33.6m31.2m28.8m14.9m21.2m13.9m9.6m5.9m8.0m27.3m27.6m33.7m27.4m

Accounts Payable

1.4m990.1k1.4m993.8k917.6k1.3m1.5m969.8k1.0m848.6k740.3k1.4m1.1m1.4m1.6m1.1m1.8m1.7m1.8m1.4m3.7m7.3m7.9m1.5m906.1k1.1m1.3m

Dividends Payable

48.3k75.7k

Current Liabilities

1.7m2.3m1.6m1.2m1.7m2.2m2.6m3.9m1.1m1.2m1.2m2.1m1.9m2.9m3.1m3.1m5.0m3.9m5.8m4.3m8.8m12.4m17.5m4.3m4.3m5.0m5.8m

Long-term debt

3.9k3.5k3.1k2.3k

Total Debt

3.9k3.5k3.1k2.3k

Total Liabilities

1.7m2.3m1.6m1.2m1.7m2.2m2.6m3.9m13.5m9.9m1.3m2.2m1.9m2.9m3.1m3.1m5.1m3.9m5.8m4.3m8.8m12.4m17.5m10.8m11.1m5.0m5.8m

Common Stock

11.4k11.4k11.4k11.4k11.4k11.9k13.5k16.0k22.0k22.0k22.3k27.9k34.2k35.4k36.1k37.3k40.4k40.7k59.3k62.0k81.8k85.0k98.8k23.8k23.8k25.7k26.1k

Preferred Stock

287.0287.0455.0917.0917.0955.0450.0450.0450.0450.0450.0450.0443.0443.0418.0420.0420.0420.0370.0370.0244.0242.0

Additional Paid-in Capital

43.9m44.0m44.3m44.3m45.1m46.7m47.6m49.5m68.7m67.3m79.4m89.2m122.6m126.8m129.0m131.5m136.3m137.7m147.1m151.4m163.0m164.2m171.4m200.6m201.2m218.7m222.5m

Retained Earnings

(74.0m)(81.7m)(85.8m)(90.5m)(98.6m)(103.5m)(112.6m)(126.8m)(131.9m)(141.9m)(162.3m)(170.9m)(181.1m)(184.2m)(184.9m)(190.1m)(201.0m)

Total Equity

3.2m737.8k423.0k(143.5k)(441.8k)(1.3m)(2.2m)(2.9m)(3.7m)(1.6m)5.6m7.6m36.9m36.4m30.5m28.1m23.8m11.0m15.4m9.7m840.7k(6.5m)(9.5m)16.5m16.5m28.7m21.6m

Debt to Equity Ratio

0 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

1.5 x4.1 x4.8 x-7.2 x-2.8 x-0.8 x-0.2 x-0.4 x-2.6 x-5.2 x1.2 x1.3 x1.1 x1.1 x1.1 x1.1 x1.2 x1.4 x1.4 x1.4 x11.4 x-0.9 x-0.8 x1.7 x1.7 x1.2 x1.3 x

CorMedix Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(4.5m)(7.1m)(910.2k)(1.5m)(2.6m)(1.3m)(3.2m)(5.7m)(16.7m)(13.2m)(18.2m)(5.5m)(9.6m)(14.3m)(4.2m)(9.1m)(18.2m)(7.6m)(12.7m)(22.7m)(10.2m)(18.7m)(29.0m)(5.2m)(5.9m)(11.1m)(5.6m)

Depreciation and Amortization

6.2k9.3k1.8k3.5k5.3k543.01.1k1.6k2.4k1.1k11.5k3.2k7.1k11.1k4.1k8.4k16.9k8.8k17.7k26.7k19.4k38.7k56.8k20.1k40.5k56.6k17.7k

Accounts Receivable

(11.8k)(52.9k)(47.4k)2.3k(40.0k)(50.2k)(15.5k)317.0k301.2k(63.5k)(133.1k)(71.6k)57.2k61.2k(247.3k)(24.0k)10.7k6.6k(7.3k)

Inventories

(270.5k)16.3k(198.0k)(597.4k)1.6k(252.0k)(236.1k)20.3k53.1k92.4k71.9k40.6k67.2k15.3k(78.7k)253.0k8.9k25.8k45.0k47.2k

Accounts Payable

297.5k(149.2k)416.1k(14.7k)(146.1k)262.9k387.4k(121.8k)117.5k(62.7k)(170.9k)546.4k256.3k538.5k(130.2k)(602.1k)47.2k80.8k117.5k(241.5k)1.8m5.5m6.1m(1.1m)(1.7m)(1.5m)309.0k

Cash From Operating Activities

(3.5m)(5.4m)(130.1k)(1.1m)(1.7m)(617.8k)(1.2m)(2.7m)(1.4m)(2.9m)(4.7m)(2.3m)(5.9m)(8.9m)(5.5m)(9.2m)(15.8m)(6.8m)(14.5m)(21.3m)(7.1m)(11.4m)(16.5m)(7.4m)(7.2m)(11.2m)(8.0m)

Purchases of PP&E

(1.6k)(1.6k)(19.6k)(25.9k)(12.9k)(13.8k)(13.8k)(1.9k)(55.1k)(2.0k)(3.9k)(26.6k)(38.2k)(38.2k)(48.9k)(19.2k)(22.7k)(27.1k)(9.9k)

Cash From Investing Activities

(1.6k)(1.6k)(19.6k)(25.9k)(12.9k)(13.4m)(23.6m)6.5m7.0m6.7m5.2m1.2m5.3m1.6m1.6m1.6m(8.0m)(11.8m)(12.3m)985.4k

Dividends Paid

54.6k33.1k

Cash From Financing Activities

(15.0k)755.0k475.0k500.0k2.3m8.3m8.3m8.3m6.8m39.1m42.4m266.0k2.4m7.1m354.2k13.2m13.2m3.3m4.1m11.0m16.0m16.0m26.0m2.8m

Net Change in Cash

(3.5m)(5.4m)(130.1k)(1.1m)(993.0k)(142.8k)(677.1k)(352.4k)6.8m5.3m3.5m4.5m19.8m9.9m1.4m203.6k(2.0m)(1.2m)(127.1k)(2.9m)(2.2m)(5.7m)(3.9m)633.2k(3.1m)2.5m(4.1m)

Interest Paid

26.9k56.7k93.5k465.0970.01.5k859.01.0k2.6k992.01.0k992.02.8k1.9k1.9k1.9k6.3k

Income Taxes Paid

6.3k

CorMedix Ratios

USDQ2, 2011

Financial Leverage

1.5 x